CJC-1295 Ipamorelin vs Tesamorelin in the Literature

Before the details

The CJC-1295 Ipamorelin vs tesamorelin comparison is mostly a comparison of evidence levels. Tesamorelin is a growth-hormone-releasing-hormone analogue that has been through randomized controlled trials and carries a regulatory approval for a specific condition. The CJC-1295 Ipamorelin stack is two research peptides used together, with a well-reasoned mechanism but no trial of the actual combination. Both raise growth hormone through the releasing-hormone pathway; the stack adds a second, ghrelin-receptor pathway via ipamorelin. Where tesamorelin has measured outcomes — visceral fat down, lean mass up, IGF-1 up, with a manageable safety profile in pooled trials — the stack has single-peptide data and synergy theory. This page lays the two side by side honestly: a strong-but-unproven combination against a trialed, approved single agent. Every number is cited.

What tesamorelin actually proved

Tesamorelin has the kind of evidence the stack lacks. A 2026 meta-analysis of five randomized controlled trials found significant reductions in visceral adipose tissue (mean difference −27.71 cm²) and hepatic fat (−4.28%), increased lean body mass (+1.42 kg) and IGF-1, with no serious adverse events or glucose perturbation ^[7]. That is pooled, controlled, human evidence for what sustained GHRH-pathway stimulation does to body composition.

Tesamorelin is itself a GHRH analogue, so it is also the best read-across for the CJC-1295 half of the stack — the half that works through the same receptor. What it cannot tell you is what adding ipamorelin's second pathway does, because tesamorelin is a single agent.

What the stack offers, and what it can't show

The CJC-1295 Ipamorelin stack's pitch is mechanistic breadth: a long-acting releasing-hormone signal (with-DAC CJC-1295 raised growth hormone and IGF-1 for days in healthy adults ^[1]) plus a selective ghrelin-receptor pulse (ipamorelin, the first selective secretagogue ^[2]), combined for supra-additive release ^[3][4]. On paper that is a richer stimulus than a single GHRH analogue.

What it cannot show is outcomes. There is no randomized controlled trial of the combination, no measured visceral-fat or lean-mass endpoint, and ipamorelin's own counter-signal — increased body fat via leptin and appetite in growth-hormone-intact mice ^[8] — means even the direction of a body-composition effect is not guaranteed. Tesamorelin shows what happened; the stack shows what should happen mechanistically.

The comparison, honestly

If the question is "which has evidence," tesamorelin wins decisively — randomized trials, pooled outcomes, an approval, a defined safety profile ^[7]. If the question is "which has the broader mechanism," the CJC-1295 Ipamorelin stack adds a second pathway tesamorelin does not touch ^[2][3]. Both share the growth-hormone-axis safety considerations — glucose, insulin sensitivity, fluid retention — set out in the secretagogue-class review ^[6]. The defensible summary is narrow: tesamorelin is a trialed, approved single GHRH analogue with measured body-composition benefits; the stack is an untested two-pathway research combination whose effects are inferred, not demonstrated. For the GHRH-only contrast, see ipamorelin vs sermorelin.